Table 2.
Different neoadjuvant chemotherapy regimes for the study group.
| Chemotherapy regime | Number of patients |
|---|---|
| No chemotherapy | 54 |
| 5-FU | 3 |
| 5-FU (BOSSET regime) | 189 |
| 5-FU + folinic acid | 18 |
| 5-FU + leucovorin | 7 |
| 5-FU + oxaliplatin | 1 |
| 5-FU + oxaliplatin + folinic acid | 1 |
| Capecitabine | 124 |
| Capecitabine + oxaliplatin | 3 |
| Cetuximab | 2 |
| CORE trial | 6 |
| De Gramont regime | 3 |
| DESCARTES | 11 |
| Mitomycin | 1 |
| Palliative chemotherapy | 1 |
| SOCRATES | 22 |
| Tomudex | 1 |
| Tomudex + oxaliplatin | 1 |
| XELOX trial | 15 |
| Total | 463 |
5-FU, 5-fluorouracil; BOSSET, regime with different doses of 5-FU; CORE trial, Phase II study – Chemoradiation with Oxaliplatin in Rectal Cancer; de Gramont regime, regime using fluorouracil and folinic acid; DESCARTES, regime using irinotecan in the chemoradiation; SOCRATES, Phase II study – oxaliplatin, capecitabine and radiotherapy; XELOX, capecitabine and oxaliplatin.